Oxford Vaccine Group and Pandemic Sciences Institute\u2019s Professor Pollard speaks to the people who shaped the COVID-19 pandemic in his new podcast, The Oxford Colloquy.
A new Future Vaccines Manufacturing Hub \u2013 co-led by University of Oxford and University College London \u2013 aims to make the UK the global centre for discovering and manufacturing next-generation vaccines.
The inaugural MRC Impact Prize recognises teams who have made outstanding impacts in health and medical research. The winners will be announced at a ceremony in the spring.
A vaccine developed by the Oxford Vaccine Group\u2019s Prof Teresa Lambe and supported in clinical trials and manufacture scale-up by researchers from the Jenner Institute (Nuffield Department of Medicine) has been recommended for inclusion in a ring vaccination trial to combat a Sudan ebolavirus outbreak in Uganda.
The Pandemic Sciences Institute is hosting the UK GOARN partners this week to discuss hot topics such as operational research and rapid response capacity during outbreaks.
The UK\u2019s efforts to tackle the monkeypox outbreak will receive a huge boost with the creation of a new research consortium \u2013 in which the University of Oxford is a key partner \u2013 working together to develop better diagnostic tests, identify potential therapies and study vaccine effectiveness.
The team behind the world-leading RECOVERY trial of COVID-19 treatments are leading a new study investigating a potential treatment for people who have been diagnosed with monkeypox. The National Institute for Health and Care Research (NIHR) has commissioned and funded the study. The first patients have now been recruited.
Dame Sarah Gilbert, 60, is a professor of vaccinology at Oxford\u2019s Jenner Institute and author, with Catherine Green, head of Oxford University\u2019s clinical biomanufacturing facility, of Vaxxers \u2013 a gripping narrative about developing the AstraZeneca vaccine that is wonderfully accessible and illuminating without dumbing down the science. She lives in Oxford with her husband and grownup triplets.
One trial. Over 47,000 participants. Nearly 200 hospital sites, across six countries. Ten results. Four effective COVID-19 treatments. And behind them all, an army of countless researchers, doctors, nurses, statisticians and supporting staff.
Exactly two years ago Prof Sir Andrew Pollard was starting to panic. \u201cWe were just waking up to the reality of Covid-19 and that we would need vaccines for our very survival,\u201d the director of the Oxford Vaccine Group told the Guardian last week
The Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT) \u2013 of which the University of Oxford is a lead partner \u2013 announced today the start of vaccinations in a Phase I clinical trial of a novel HIV vaccine candidate.
![\"Professor](\"https://www.psi.ox.ac.uk/news-and-opinion/professor-sir-andrew-pollard-reveals-unique-insights-into-the-world-of-science-in-a-new-podcast/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n